RT Journal Article
T1 Expression and characterization of recombinant Par j 1 and Par j 2 resembling the allergenic epitopes of Parietaria judaica pollen.
A1 Dorofeeva, Yulia
A1 Colombo, Paolo
A1 Blanca, Miguel
A1 Mari, Adriano
A1 Khanferyan, Roman
A1 Valenta, Rudolf
A1 Focke-Tejkl, Margarete
K1 Biophysical Phenomena
K1 Cell Line
K1 Cross Reactions
K1 Epitopes
K1 Escherichia coli
AB The weed wall pellitory, Parietaria judaica, is one the most important pollen allergen sources in the Mediterranean area causing severe symptoms of hay fever and asthma in allergic patients. We report the expression of the major Parietaria allergens, Par j 1 and Par j 2 which belong to the family of lipid transfer proteins, in insect cells. According to circular dichroism analysis and gel filtration, the purified allergens represented folded and monomeric proteins. Insect cell-expressed, folded Par j 2 exhibited higher IgE binding capacity and more than 100-fold higher allergenic activity than unfolded Escherichia coli-expressed Par j 2 as demonstrated by IgE ELISA and basophil activation testing. IgE ELISA inhibition assays showed that Par j 1 and Par j 2, contain genuine and cross-reactive IgE epitopes. IgG antibodies induced by immunization with Par j 2 inhibited binding of allergic patients IgE to Par j 1 only partially. IgE inhibition experiments demonstrated that insect cell-expressed Par j 1 and Par j 2 together resembled the majority of allergenic epitopes of the Parietaria allergome and therefore both should be used for molecular diagnosis and the design of vaccines for allergen-specific immunotherapy of Parietaria allergy.
PB Nature Publishing Group
YR 2019
FD 2019-10-21
LK http://hdl.handle.net/10668/15067
UL http://hdl.handle.net/10668/15067
LA en
NO Dorofeeva Y, Colombo P, Blanca M, Mari A, Khanferyan R, Valenta R, et al.  Expression and characterization of recombinant Par j 1 and Par j 2 resembling the allergenic epitopes of Parietaria judaica pollen. Sci Rep. 2019 Oct 21;9(1):15043
NO T his work was funded by the Austrian Science Fund (FWF), projects DK W1248-B30, F4605, P29991 and the Medical University of Vienna. Rudolf Valenta is a recipient of a Megagrant of the Government of the Russian Federation, grant number 14.W03.31.0024. We thank Prof Ryosuke Nakamura for kindly providing the huRBL cell line.
DS RISalud
RD Apr 18, 2025